1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-08-18 pm EDT
249.70 USD   -0.35%
08/18AMGEN INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
08/17AMGEN INC. : Ex-dividend day for
FA
08/16AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act”
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen Says FDA Approves Riabni to Treat Rheumatoid Arthritis

06/06/2022 | 11:50am EDT


© MT Newswires 2022
All news about AMGEN INC.
08/18AMGEN INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits ..
AQ
08/17AMGEN INC. : Ex-dividend day for
FA
08/16AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act&rd..
PU
08/16AMGEN CHRONICLES : Fresh Water and Fresher Ideas About Sustainability in Puerto Rico
PU
08/12AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act&rd..
PU
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
08/11Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
RE
08/11Senate finance committee chairman wyden sends amgen letter inqui…
RE
08/09Atlantic Equities Adjusts Amgen's Price Target to $182 from $190, Keeps Underweight Rat..
MT
08/08AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act&rd..
PU
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 162 M - -
Net income 2022 6 252 M - -
Net Debt 2022 27 064 M - -
P/E ratio 2022 21,2x
Yield 2022 3,11%
Capitalization 134 B 134 B -
EV / Sales 2022 6,14x
EV / Sales 2023 5,83x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 249,70 $
Average target price 250,10 $
Spread / Average Target 0,16%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.10.99%133 572
JOHNSON & JOHNSON-2.51%440 598
ELI LILLY AND COMPANY14.66%301 034
PFIZER, INC.-17.73%276 521
ROCHE HOLDING AG-16.47%273 077
ABBVIE INC.4.35%250 080